PEMETREXED SYNTHON 500 MG/20 ML I.V. INF. VIAL

It is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) a specific type of NSCLC. It is not indicated for patients who have a different type of NSCLC called squamous cell. It is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC) a specific type of NSCLC to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. It is not indicated for patients who have a different type of NSCLC called squamous cell. It is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC) a specific type of NSCLC after prior chemotherapy. It is not indicated for patients who have a different type of NSCLC called squamous cell. It is a treatment for malignant pleural mesothelioma. Dose: Once every 21 days.